ARTICLE | Company News

Roche sales and marketing update

March 26, 2012 7:00 AM UTC

Roche launched Zelboraf vemurafenib in the U.K. to treat unresectable or metastatic melanoma in patients with BRAF V600 mutations. The European Commission approved an MAA for the oral small molecule inhibitor of the oncogenic BRAF V600E gene for the indication last month The list price is £7,000 ($11,079) per four-week treatment (see BioCentury, Feb. 27). ...